Ventilator-Associated Pneumonia Caused by Pseudomonas aeruginosa: Cap Your Needles!
Abstract
The advent of the recombinant DNA revolution, which made available powerful techniques such as cloning and mutational analyses, has been a boon for the field of bacterial pathogenesis. We now know the mechanistic details of many bacterial toxins, including their enzymatic activities, multimeric states, processing, cofactors, and host cell substrates. In many cases, the exact amino acids necessary for each step of the pathogenic mechanism have been determined. However, the torrent of advances made in our understanding of molecular pathogenesis has led to only a trickle of novel therapies to help clinicians combat these bacterial infections. Vaccine development has been arguably quite successful, but most new antibiotics are still found by screening compound libraries and modifying existing antibiotic scaffolds. For physicians treating bacterial infections, was the promise of the recombinant DNA revolution merely a mirage, always receding just beyond the horizon of the clinic?
Fortunately, recent events suggest that the fruits of the recombinant DNA revolution are not truant but merely tardy to the field of bacterial infections. The translational research spigot is slowly opening, allowing for the preclinical development of an array of compounds that inhibit virulence factors discovered and characterized with the aid of recombinant DNA technology. For example, in the Pseudomonas aeruginosa field alone, anti-infective agents targeting quorum-sensing, biofilm development,…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 39 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.